ALGS (Aligos Therapeutics) Current Accrued Expense: $7.77 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALGS Aligos Therapeutics Inc ALGS
44 GF Score
Price $4.08
GF Value $2.76
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Current Accrued Expense?

Aligos Therapeutics ALGS -12.63% 44 Current Accrued Expense is $7.77 Mil as of Mar. 2026. GuruFocus rates ALGS with a GF Score™ of 44/100 and a GF Value™ of $2.76 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Aligos Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $7.77 Mil.

Aligos Therapeutics's quarterly Current Accrued Expense declined from Sep. 2025 ($8.33 Mil) to Dec. 2025 ($6.06 Mil) but then increased from Dec. 2025 ($6.06 Mil) to Mar. 2026 ($7.77 Mil).

Aligos Therapeutics's annual Current Accrued Expense declined from Dec. 2023 ($9.66 Mil) to Dec. 2024 ($9.17 Mil) and declined from Dec. 2024 ($9.17 Mil) to Dec. 2025 ($6.06 Mil).

Aligos Therapeutics Current Accrued Expense Related Terms

Aligos Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics Current Accrued Expense Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 1.24 1.47 9.66 9.17 6.06

Aligos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.40 6.58 8.33 6.06 7.77
ALGS
44GF Score
Aligos Therapeutics Inc ALGS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $7.77 Mil mean?
Aligos Therapeutics (ALGS) has a Current Accrued Expense of $7.77 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' Current Accrued Expense too high?
Aligos Therapeutics' current Current Accrued Expense is $7.77 Mil. Overall, Aligos Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Current Accrued Expense compare to SNTI and NTRB?
Aligos Therapeutics' Current Accrued Expense of $7.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Aligos Therapeutics and its competitors. Aligos Therapeutics's current Current Accrued Expense is $7.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.76, compared to a current price of $4.08 — trading 47.8% above its estimated fair value. The current Current Accrued Expense is $7.77 Mil. Aligos Therapeutics' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Current Accrued Expense is $7.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of $4.08 is trading 47.8% above its estimated GF Value™ of $2.76. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for ALGS:

  • Current Accrued Expense: $7.77 Mil
  • GF Value™: $2.76 vs. price of $4.08 (47.8% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score

Get the complete analysis for ALGS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.08
Price
$2.76
GF Value